Skip to content
DataLookout
Menu

NCT04940299

Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma

StatusTerminated
PhasePhase 2
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 14 versions: 10 with changes below, 4 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Stopped Trial terminated Sponsor's reason: \<75% participation
    • Primary completion date changed from estimate of Dec 31, 2027 to Nov 11, 2026
  2. Notable Eligibility criteria shortened, about 6 words
    • Secondary endpoints: details revised at 3 of 3 entries
    • Study description revised
    • Publications: details revised at 2 of 2 entries
  3. Notable Primary and study completion dates: Dec 31, 2025 to Dec 31, 2027v11
  4. Notable Primary and study completion dates: Dec 31, 2024 to Dec 31, 2025v9
  5. Minor Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 55 to confirmed 35
    • Site details revised
    v7
Show 4 earlier versionsHide 4 earlier versions
  1. Notable Eligibility criteria expanded, about 4 words
    • Study description expanded, about 66 words
    v6
  2. Notable Primary and study completion dates: Dec 31, 2023 to Dec 31, 2024
    • Eligibility criteria expanded, about 64 words
    v5
  3. Notable Primary and study completion dates: Jun 30, 2023 to Dec 31, 2023v4
  4. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Nov 5, 2021 to Sep 23, 2021
    • Site details revised
    v2
  1. Study First Submitted
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Incidence of dose limiting toxicity
Timeframe: Up to 2 years
Occurrence of one or more grade 3 or higher adverse event in a given patient (Cohort 1)
Timeframe: Up to 2 years

Secondary (3)

Best overall response
Progression-free survival (PFS)
Overall survival (OS)

Arms and interventions

Cohort 1 (ipilimumab, nivolumab, tocilizumab)Experimental

Patients with melanoma will receive ipilimumab IV over 90 minutes and nivolumab IV over 30 minutes on day 1. Treatment with ipilimumab and nivolumab repeats every 3 weeks for 4 doses, then treatment with nivolumab repeats every 4 weeks for 2 years in the absence of disease progression or unacceptable toxicity. Cohort 1 will be divided into 2 sub-groups: sub-group 1 of 25 patients, and subgroup 2 of 10 patients that will consist of varying Tocilizumab administration doses. For sub-group 1, Tocilizumab 162mg will be administered subcutaneously every 2 weeks starting week 0, up to 12 weeks for a total of 6 doses. For sub-group 2 , Tocilizumab 162mg will be administered subcutaneously once every week starting at week 0 up to week 6 followed by Tocilizumab administered subcutaneously every 2 weeks starting at week 6 up to 12 weeks for a total of 9 doses.

Cohort 2 (ipilimumab, nivolumab, tocilizumab)Experimental

Patients with urothelial cancer will receive ipilimumab IV over 90 minutes and nivolumab IV over 30 minutes on day 1. Treatment with ipilimumab and nivolumab repeats every 3 weeks for 4 doses, then treatment with nivolumab repeats every 4 weeks for 2 years in the absence of disease progression or unacceptable toxicity. Starting on week 1, patients also receive tocilizumab SC every 2 weeks for up to 12 weeks (6 doses) in the absence of disease progression or unacceptable toxicity.

Cohort 3 (ipilimumab,, nivolumab, tocilizumab)Experimental

Patients with NSCLC receive ipilimumab IV over 90 minutes every 6 weeks and nivolumab IV over 30 minutes every 2 weeks for up to 2 years. Patients also receive tocilizumab SC every 2 weeks for up to 12 weeks (6 doses). Treatment continues in the absence of disease progression or unacceptable toxicity.

Biologicals: Ipilimumab, Nivolumab, Tocilizumab

Sites

1 site in 1 country

  • M D Anderson Cancer CenterHouston, Texas, United States